Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology,
particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor …

We report an approach for cancer phenotyping based on targeted sequencing of cell-free
DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of …

Simple Summary Circulating tumor DNA (ctDNA) is a non-invasive method of identifying and
monitoring genitourinary cancers, including prostate, bladder, and renal cell carcinoma, via …

Background cfDNA fragmentomics-based liquid biopsy is a potential option for noninvasive
bladder cancer (BLCA) detection that remains an unmet clinical need. Methods We …

Introduction In the era of precision medicine, liquid biopsy rapidly emerges as an integrative
diagnostic tool to successfully stratify solid tumor patients in accordance with molecular …

ABSTRACT Introduction The 11th Annual 2024 Coffey‐Holden Prostate Cancer Academy
(CHPCA) Meeting, was themed “Personalized Medicine: Leave No Patient Behind,” and was …

The progress that has been made in recent years in relation to liquid biopsies in general and
circulating tumor DNA (ctDNA) in particular can be seen as groundbreaking for the future of …

Introduction The liquid biopsy is a breakthrough in the field of medical diagnostics. It serves
as a sentinel that can quietly detect even the subtlest aberrations that indicate the presence …

Cancer is a prominent global cause of mortality, primarily due to delayed detection leading
to limited treatment options. Current screening methods are mostly invasive and involve …

Introduction: Early cancer detection can lead to improved outcomes and a shift toward a
prevention model. This review explores the role of artificial intelligence (AI) in early cancer …